Latest news with #pipeline
Yahoo
9 hours ago
- Business
- Yahoo
Should You Buy Pembina Pipeline While it's Below $60?
Written by Chris MacDonald at The Motley Fool Canada Pembina Pipeline (TSX:PPL) is among the top pipeline stocks I don't think gets enough love. There are reasons for this, with other prominent players in the energy infrastructure space generally taking up significant mind share for investors, and for good reason. That said, I think Pembina is an intriguing stock trading around 15% below the company's all-time high of roughly $60 per share. Let's dive into what to make of this stock at current levels and whether Pembina is worth adding as a long-term hold right now. Pembina is among the leading Canada-based pipeline companies providing extensive exposure to the energy sector in a much less volatile fashion than many energy producers. With a robust and integrated network of pipelines, export terminals and processing facilities, Pembina stands as a top option in this space for investors seeking defensive exposure in this market. That said, the company's fundamentals really stand out to me as a key reason why this is a stock that ought to be considered. In the company's first quarter, Pembina reported strong revenue and earnings growth, with top-line revenue rising a whopping 58%. The pipeline giant's earnings per share rose nearly 10% on this report, as Pembina's profitability and efficiency initiatives also flowed through to the bottom line. Yes, I would like to see more bottom-line growth from Pembina over time. But with this earnings surge, the company's dividend yield of 5.6% looks much more stable, and should position long-term investors well for whatever environment is ahead. Of course, I'm always on the lookout for stocks that have been unfairly beaten up. I don't think that's the case with Pembina at this juncture, considering the stock is pretty close to trading near its all-time high. That said, at this discount to Pembina's previous high, I can certainly see a strong case for why investors may want to consider this energy infrastructure play. In my books, Pembina is a top pipeline operator worth considering for those looking for more defensive dividend stocks in this environment. The post Should You Buy Pembina Pipeline While it's Below $60? appeared first on The Motley Fool Canada. Before you buy stock in Pembina Pipeline, consider this: The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Pembina Pipeline wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $24,927.94!* Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 30 percentage points since 2013*. See the Top Stocks * Returns as of 6/23/25 More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool recommends Pembina Pipeline. The Motley Fool has a disclosure policy. 2025 Sign in to access your portfolio
CBC
a day ago
- Business
- CBC
First Nations on B.C.'s North Coast say they would not support a new pipeline
The president of an organization representing First Nations along the north coast of B.C. says it would not support any new pipeline projects in northern B.C. Alberta Premier Danielle Smith told Bloomberg News Tuesday that she expects a private company will bring forward a proposal to build a new oil pipeline to B.C.'s North Coast within weeks. Smith wants to revive a plan to bring oilsands crude to the northern B.C. coast for export to Asia, with the endpoint in Prince Rupert, B.C. "There is no project or proponents that would be acceptable to us on the North Coast," said Marilyn Slett, elected chief councillor of the Heiltsuk Tribal Council, about 479 kilometres north of Vancouver, and president of the Coastal First Nations' Great Bear Initiative (CFN)—an alliance of nine First Nations on the north Pacific coast of B.C. to Haida Gwaii. "Anything that proposes to send oil through the coast is a non-starter," said Slett. Many of the CFN First Nations were parties to a B.C. Supreme Court appeal that stopped Northern Gateway pipeline plans to ship crude oil from the port of Kitimat, B.C. The Enbridge project was scrapped because the court ruled Ottawa failed to properly consult with First Nations affected by the pipeline. Slett said that CFN does support reliable energy projects like solar and hydroelectric. "[The] north Pacific coast is one of the richest cold water marine ecosystems on earth and it's a source of our sustenance, tied to our culture and the livelihoods of not just our communities but many British Columbians," said Slett. "We can't have one livelihood at the cost of another," she said. A University of British Columbia Study estimated that a major oil spill cleanup on the North Coast could cost up to $9.6 billion, and cost the region's commercial fisheries, port, ferry transportation and tourism industries more than $300 million. B.C. premier won't take position B.C. Premier David Eby has not given a firm position on whether he would support a pipeline through northern B.C, telling CBC The Early Edition on Thursday, "I won't speculate about a project that doesn't exist." But did say he would not support a publicly funded pipeline to the North Coast. Premier Eby discusses possibility of northern oil pipeline 1 day ago Duration 13:36 Alberta Premier Danielle Smith says a proposal to build an oil pipeline to B.C.'s North Coast could be just weeks away. For his part, B.C. Premier David Eby has said he opposes a publicly-funded pipeline, but may consider a privately backed project. He joined CBC's Stephen Quinn to respond to Smith and discuss the possible proposal. Eby told CBC that his government is in support of the federal oil tanker ban on the North Coast. The Oil Tanker Moratorium Act prohibits oil tankers carrying more than 12,500 metric tons of crude oil, or persistent oil products, from stopping, loading, or unloading at ports in a restricted area covering nearly the entire North Coast. Slett said she would like Eby's government to take a position on a potential pipeline. "Theoretically or not, these discussions are happening," said Slett. 'Knee-jerk reaction' The B.C. regional chief for the Assembly of First Nations, Terry Teegee, said that First Nations have a right to be concerned about Eby's comments, but that these discussions are premature. Teegee said that this is a "knee-jerk reaction" to tariffs from the U.S. administration, which has led the province to diversify its trade relationships. Eby recently returned from a 10-day trade mission to East Asia, where Japanese conglomerates expressed interest in the liquefied natural gas (LNG) from the province. "We've got partners over there that prefer to buy B.C. LNG because it comes from a politically stable jurisdiction, but also because it is the lowest carbon LNG in the world," Eby told CBC. LNG has started producing liquefied natural gas that is being transported by the Coastal GasLink pipeline to an export facility in Kitimat, B.C. "It is really concerning because some of these projects will have long-lasting impacts to many First Nations that would affect their territories [for] decades, if not hundreds of years," said Teegee. Teegee said First Nations need to be part of the decision-making process when it comes to large energy projects being considered and approved. "This one is, as we've seen previously, it failed," said Teegee. "Perhaps it's a pipe dream."
Bloomberg
a day ago
- Business
- Bloomberg
Germany Considers Tighter Investment Rules Amid Nord Stream 2 Rumors
The German government is examining measures that could help it stop a potential sale of the Nord Stream 2 pipeline after speculation emerged earlier this year over reviving pipeline gas deliveries from Russia. Berlin is considering amending the legal basis for investment screening, the economy ministry said in response to a parliamentary inquiry from Green party lawmakers including Michael Kellner, which was first reported by Der Spiegel magazine on Friday.
Washington Post
2 days ago
- Climate
- Washington Post
NTSB says company failed to shut down oil pipeline for nearly 13 hours after pressure dropped
Roughly 1.1 million gallons of crude oil spilled from a pipeline into the Gulf of Mexico in November 2023 because operators failed to shut it down for nearly 13 hours after gauges first hinted at a problem, the National Transportation Safety Board said Thursday. The NTSB said the leak off the coast of Louisiana was the result of underwater landslides, caused by hazards such as hurricanes, that pipeline owner Third Coast failed to address even though the threats were well known in the industry.
Globe and Mail
2 days ago
- Business
- Globe and Mail
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck MRK has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease. Merck's phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. The company is now positioned to launch around 20 new vaccines and drugs over the next few years, with many having blockbuster potential. Merck has several promising candidates in late-stage development, such as enlicitide decanoate/MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis, bomedemstat/MK-3543 for essential thrombocythemia, myelofibrosis and polycythemia vera and Daiichi-Sankyo-partnered antibody-drug conjugates (ADCs). Merck and Daiichi Sankyo are co-developing three DXd ADCs — patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan for several types of cancer indications. To foray into the lucrative obesity market, Merck has in-licensed global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from China-based biotech Hansoh Pharma. MRK's Keytruda Faces Patent Expiration in 2028 As Merck prepares for Keytruda's eventual loss of exclusivity in 2028, the company's expanding pipeline and new products are expected to play a key role in shaping its future business mix. Besides working on various strategies to drive Keytruda's long-term growth, Merck is also pinning hopes on its new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension (PAH) drug, Winrevair, to boost its top line once Keytruda loses exclusivity. Both products have witnessed a strong launch so far. Merck's long-acting monoclonal antibody, Enflonsia (clesrovimab), for the prevention of respiratory syncytial virus was approved by the FDA earlier this month. Keytruda, a PD-L1 inhibitor approved for several types of cancer, generated sales of $7.21 billion in the first quarter of 2025, up 6% year over year. Our model estimates for Keytruda suggest a CAGR of 5.4% over the next three years. However, at present, it is not quite clear whether Merck's new products and pipeline candidates can help the company successfully navigate the Keytruda LOE period and potential competition for the drug. PD-L1 Inhibitors Competing With Keytruda Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers ' BMY Opdivo, Roche 's RHHBY Tecentriq and AstraZeneca 's AZN Imfinzi. BMY's Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.26 billion in Opdivo sales during the first quarter of 2025, up 9% year over year. Tecentriq is Roche's leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 870 million in Tecentriq sales in the first quarter of 2025. AZN's Imfinzi generated sales of $1.26 billion in the first quarter of 2025, up 16%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca's oncology portfolio. MRK's Price Performance, Valuation and Estimates Year to date, shares of Merck have lost 19.9% compared with the industry 's decrease of 1.8%. From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.56 forward earnings, lower than 14.92 for the industry and its 5-year mean of 12.85. The Zacks Consensus Estimate for 2025 earnings has declined from $8.94 per share to $8.92, while the same for 2026 has decreased from $9.79 to $9.73 over the past 60 days. Merck has a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
